# A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.

> **NCT00545532** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 228 (actual)

## Conditions studied

- Influenza, Human

## Interventions

- **DRUG:** oseltamivir
- **OTHER:** placebo

## Key facts

- **NCT ID:** NCT00545532
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02-04
- **Primary completion:** 2017-05-02
- **Final completion:** 2017-05-02
- **Target enrollment:** 228 (ACTUAL)
- **Last updated:** 2018-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00545532

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00545532, "A Study of Oseltamivir (Tamiflu) for Treatment of Influenza in Immunocompromised Participants.". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT00545532. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*